Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Karvezide, irbesartan,hydrochlorothiazide, Date of authorisation: 16/10/1998, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Date of authorisation: 14/10/1998, Revision: 53, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Sunlenca, lenacapavir sodium, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), PIP number: P/0372/2024

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): ProQuad, measles, mumps, rubella and varicella vaccine (live), Date of authorisation: 05/04/2006, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Riulvy, tegomil fumarate, Date of authorisation: 28/07/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lacosamide Adroiq, lacosamide, Date of authorisation: 31/05/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Date of authorisation: 26/05/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, emtricitabine,rilpivirine,tenofovir alafenamide, Date of authorisation: 19/08/2025, Status: Authorised